These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21071389)

  • 1. Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer.
    Hatano K; Nonomura N; Nishimura K; Kawashima A; Mukai M; Nagahara A; Nakai Y; Nakayama M; Takayama H; Tsujimura A; Okuyama A
    Jpn J Clin Oncol; 2011 Feb; 41(2):253-9. PubMed ID: 21071389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.
    Nishimura K; Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Imazu T; Takaha N; Sugao H; Miki T; Okuyama A
    Oncology; 2001; 60(1):49-54. PubMed ID: 11150908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormonal chemotherapy for hormone-refractory prostate cancer].
    Nishimura K; Nakai Y; Shimizu K; Tokizane T; Arai Y; Inoue H; Takaha N; Nonomura N; Okuyama A; Kamoi K; Ukimura O; Miki T; Koide T; Ichikawa Y; Nishimura K; Sugao H; Yamaguchi S; Takatera H; Uchida K; Miura H
    Hinyokika Kiyo; 2002 Nov; 48(11):713-8. PubMed ID: 12512147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
    Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
    Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
    Glode LM; Barqawi A; Crighton F; Crawford ED; Kerbel R
    Cancer; 2003 Oct; 98(8):1643-8. PubMed ID: 14534880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience of oral hormone-chemotherapy in prostatic cancer].
    Fujita K; Munakata A
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1691-4. PubMed ID: 1872625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin.
    Tsunoda A; Nakao K; Watanabe M; Matsui N; Tsunoda Y
    Jpn J Clin Oncol; 2010 May; 40(5):412-9. PubMed ID: 20085907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
    Miyake H; Hara I; Yamazaki H; Eto H
    Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
    Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
    Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ifosfamide in combined hormonochemotherapy on prostate cancer].
    Fujita K; Matsushima H; Nakano M; Kaneko T
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):227-30. PubMed ID: 8311493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
    Uchida K; Takeshima H; Kikuchi K; Shimazui T; Miyanaga N; Kawai K; Akaza H; Tsuchiya A; Noguchi R; Hattori K; Manabe F; Matsuki K; Suzuki R; Ishikawa S; Kondo F; Kobayashi T; Koiso K
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
    Prescrire Int; 2002 Apr; 11(58):44-7. PubMed ID: 11987311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemo-endocrine therapy with low-dose cisplatin, UFT, and dexamethasone for hormone-refractory prostate cancer patients].
    Kawaguchi T; Mayama I; Iwabuchi I; Ogasawara M; Tsukui A
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1921-5. PubMed ID: 20948257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer.
    Ogawa Y; Ishikawa T; Chung SH; Ikeda K; Takashima T; Onoda N; Nakata B; Nishiguchi Y; Hirakawa K
    Anticancer Res; 2003; 23(4):3453-7. PubMed ID: 12926089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral antineoplastic agents for prostate cancer].
    Kume H
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():522-4. PubMed ID: 22208037
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.
    Flaig TW; Barqawi A; Miller G; Kane M; Zeng C; Crawford ED; Glodé LM
    Cancer; 2006 Jul; 107(2):266-74. PubMed ID: 16779800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.